CureVac
CVAC
CVAC was delisted on the 5th of January, 2026.
83 hedge funds and large institutions have $56.4M invested in CureVac in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 33 reducing their positions, and 22 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less call options, than puts
Call options by funds: $2.88M | Put options by funds: $2.89M
0.66% less ownership
Funds ownership: 4.47% → 3.81% (-0.66%)
6% less funds holding
Funds holding: 88 → 83 (-5)
23% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 22
36% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 33
51% less capital invested
Capital invested by funds: $114M → $56.4M (-$58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
+$3.29M |
| 2 |
Renaissance Technologies
New York
|
+$1.16M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$632K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
+$572K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$3.91M |
| 2 |
Goldman Sachs
New York
|
-$3.24M |
| 3 |
Jane Street
New York
|
-$1.86M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.71M |
| 5 |
HF
HRT Financial
New York
|
-$1.48M |
CVAC Hedge Fund Activity: Q3 2022 in Review
83 of the 5,827 institutional investors tracked by Wall St. Rank reported a position in CureVac (CVAC) for Q3 2022, worth a combined $56.4M — down 51% from $114M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of CVAC and 17 opened new positions — a net loss of 5 holders — while 33 trimmed existing stakes and 21 added.
The largest buyer was Man Group, opening a new position worth an estimated $3.29M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $3.91M sold.
- 83 institutional investors held CureVac (CVAC) as of Q3 2022, down from 88 in Q2 2022.
- Funds reported $56.4M of CureVac stock for Q3 2022, down 51% quarter-over-quarter.
- 17 funds opened new CureVac positions in Q3 2022 and 22 closed out, a net change of -5 holders.
- The largest CureVac buyer in Q3 2022 was Man Group, an estimated $3.29M added.
- The largest CureVac seller in Q3 2022 was Baillie Gifford & Co, an estimated $3.91M sold.
Based on aggregated 13F filings for Q3 2022.